These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 8500920)

  • 1. Variation of Cmax and Cmax/AUC in investigations of bioequivalence.
    Endrenyi L; Yan W
    Int J Clin Pharmacol Ther Toxicol; 1993 Apr; 31(4):184-9. PubMed ID: 8500920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cmax/AUC is a clearer measure than Cmax for absorption rates in investigations of bioequivalence.
    Endrenyi L; Fritsch S; Yan W
    Int J Clin Pharmacol Ther Toxicol; 1991 Oct; 29(10):394-9. PubMed ID: 1748540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Choice of characteristics and their bioequivalence ranges for the comparison of absorption rates of immediate-release drug formulations.
    Schall R; Luus HG; Steinijans VW; Hauschke D
    Int J Clin Pharmacol Ther; 1994 Jul; 32(7):323-8. PubMed ID: 7952792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of absorption rates in bioequivalence studies of immediate release drug formulations.
    Schall R; Luus HG
    Int J Clin Pharmacol Ther Toxicol; 1992 May; 30(5):153-9. PubMed ID: 1592542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on the statistical analysis of bioequivalence studies.
    Steinijans VW; Hauschke D
    Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S45-50. PubMed ID: 1601531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on the statistical analysis of bioequivalence studies.
    Steinijans VW; Hauschke D
    Int J Clin Pharmacol Ther Toxicol; 1990 Mar; 28(3):105-10. PubMed ID: 2318545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A limited sampling approach in bioequivalence studies: application to long half-life drugs and replicate design studies.
    Mahmood I; Mahayni H
    Int J Clin Pharmacol Ther; 1999 Jun; 37(6):275-81. PubMed ID: 10395118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic characteristics for extent of absorption and clearance in drug/drug interaction studies.
    Schall R; Hundt HK; Luus HG
    Int J Clin Pharmacol Ther; 1994 Dec; 32(12):633-7. PubMed ID: 7881699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic analysis of bioequivalence trials: implications for sex-related issues in clinical pharmacology and biopharmaceutics.
    Chen ML; Lee SC; Ng MJ; Schuirmann DJ; Lesko LJ; Williams RL
    Clin Pharmacol Ther; 2000 Nov; 68(5):510-21. PubMed ID: 11103754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An area correction method to reduce intrasubject variability in bioequivalence studies.
    Abdallah HY
    J Pharm Pharm Sci; 1998; 1(2):60-5. PubMed ID: 10945919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
    Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
    Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative bioavailability of two capsule formulations of mefenamic acid.
    Rawashdeh NM; Najib NM; Jalal IM
    Int J Clin Pharmacol Ther; 1997 Aug; 35(8):329-33. PubMed ID: 9266288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Limits of 80%-125% for AUC and 70%-143% for Cmax. What is the impact on bioequivalence studies?
    Hauck WW; Parekh A; Lesko LJ; Chen ML; Williams RL
    Int J Clin Pharmacol Ther; 2001 Aug; 39(8):350-5. PubMed ID: 11515710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
    Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
    Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of changing the bioequivalence range from (0.80, 1.20) to (0.80, 1.25) on the power and sample size.
    Steinijans VW; Hauck WW; Diletti E; Hauschke D; Anderson S
    Int J Clin Pharmacol Ther Toxicol; 1992 Dec; 30(12):571-5. PubMed ID: 1473872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partial-area method in bioequivalence assessment: naproxen.
    Niazi SK; Alam SM; Ahmad SI
    Biopharm Drug Dispos; 1997 Mar; 18(2):103-16. PubMed ID: 9099447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Geometric mean ratio-dependent scaled bioequivalence limits with leveling-off properties.
    Karalis V; Macheras P; Symillides M
    Eur J Pharm Sci; 2005 Sep; 26(1):54-61. PubMed ID: 15955680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioequivalence study of two capsule formulations of omeprazole.
    Pillai GK; Salem MS; Najib NM; Jilani J; Hasan MM; Ghanem E; Sallam E; Shubair MS; al-Delq S
    Acta Pharm Hung; 1996 Nov; 66(6):231-5. PubMed ID: 9604487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bioequivalence of an optimized doxycycline preparation].
    Lode H; Deppermann N; Schmidt U
    Arzneimittelforschung; 1989 Sep; 39(9):1162-5. PubMed ID: 2590269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative bioavailability of different valproic acid formulations.
    Franke G; Diletti E; Hoffmann C; Zschiesche M; Scheuch E; Siegmund W
    Int J Clin Pharmacol Ther; 1995 Dec; 33(12):653-7. PubMed ID: 8963482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.